Hims & Hers Health ( (HIMS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Hims & Hers Health shares have taken a hit after a court ruling against the Outsourcing Facilities Association’s motion regarding Eli Lilly’s tirzepatide, which could spell trouble for Hims & Hers’ reliance on compounded drugs like semaglutide. Adding to the pressure, Novo Nordisk’s new direct-to-consumer platform for its weight-loss drug Wegovy intensifies competition. Analysts are divided, with some expressing caution due to these regulatory and competitive hurdles affecting the company’s growth and revenue targets.
More about Hims & Hers Health
YTD Price Performance: 62.26%
Average Trading Volume: 19,629,296
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9B
For further insights into HIMS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.